These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 1102243)
21. Talking about Toxicity - "What We've Got Here Is a Failure to Communicate". Sacks CA; Miller PW; Longo DL N Engl J Med; 2019 Oct; 381(15):1406-1408. PubMed ID: 31597018 [No Abstract] [Full Text] [Related]
22. The case for recording events in clinical trials. Skegg DC; Doll R Br Med J; 1977 Dec; 2(6101):1523-4. PubMed ID: 338116 [TBL] [Abstract][Full Text] [Related]
24. [Role and significance of clinico-pharmacological investigations in drug research]. Simon K Acta Pharm Hung; 1978; 48 Suppl():44-9. PubMed ID: 373387 [No Abstract] [Full Text] [Related]
25. Iatrogenic disease: an epidemiologic perspective. Sartwell PE Int J Health Serv; 1974; 4(1):89-93. PubMed ID: 4829900 [No Abstract] [Full Text] [Related]
27. The issue of side effects and the "blind ability" of clinical drug trials. Katz R; Deveaugh-Geiss J Am J Psychiatry; 1993 Nov; 150(11):1759-60; author reply 1760-1. PubMed ID: 8214202 [No Abstract] [Full Text] [Related]
28. The issue of side effects and the "blind ability" of clinical drug trials. Duberstein PR Am J Psychiatry; 1993 Nov; 150(11):1760; author reply 1760-1. PubMed ID: 8214203 [No Abstract] [Full Text] [Related]
29. Towards rational drug therapy in old age. The F.E. Williams Lecture 1985. Caird FI J R Coll Physicians Lond; 1985 Oct; 19(4):235-9. PubMed ID: 4067897 [No Abstract] [Full Text] [Related]
30. Minimum acceptable requirements for introduction and marketing of drugs. Lasagna L Drugs; 1974; 7(6):409-13. PubMed ID: 4422210 [No Abstract] [Full Text] [Related]
31. Unapproved drug use: compassionate or cause for concern? Ross E Lancet Neurol; 2009 Feb; 8(2):136-7. PubMed ID: 19161905 [No Abstract] [Full Text] [Related]
32. Post-marketing surveillance: drug epidemiology. Borden EK J Int Med Res; 1981; 9(6):401-7. PubMed ID: 7319130 [TBL] [Abstract][Full Text] [Related]
33. Compensation and drug trials. Diamond AL; Laurence DR Br Med J (Clin Res Ed); 1983 Sep; 287(6393):675-7. PubMed ID: 6411277 [TBL] [Abstract][Full Text] [Related]
34. Can postmarketing surveillance help to effect optimal drug therapy? Strom BL; Melmon KL JAMA; 1979 Nov; 242(22):2420-2. PubMed ID: 385922 [TBL] [Abstract][Full Text] [Related]
35. Phase II trials: use of a clinical tumor panel and overview of current resources and studies. Muggia FM; Rozencweig M; Chiuten DF; Jensen-Akula MS; Charles LM; Kubota TT; Bono VH Cancer Treat Rep; 1980 Jan; 64(1):1-9. PubMed ID: 6991100 [No Abstract] [Full Text] [Related]